Disease caused by Neisseria meningitidis is associated with high mortality rates and significant sequelae. Quadrivalent (A, C, Y, W-135) polysaccharide meningococcal vaccine has been available for more than 20 years, and although used widely for adolescents entering college, it has a number of limitations, including short duration of immunity and lack of a herd effect. A quadrivalent meningococcal conjugate vaccine has recently been licensed and endorsed for use in adolescents 11 to 12 years of age, at age 15, or at college entry. Among the key features of the new meningococcal conjugate vaccine are stimulation of both B-cell-dependent and T-cell-dependent immune responses, induction of immunologic memory and booster effects, long-term protection, reduction of nasopharyngeal carriage of N. meningitidis, and herd immunity. Large randomized, double-blind studies in adolescents and 2- to 10-year olds have demonstrated the immunogenicity as well as the safety and tolerability of the new meningococcal conjugate vaccine formulation.
Get full access to this article
View all access options for this article.
References
1.
Rosenstein N, Perkins B, Stephens D, et al.The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999;180:1894.
2.
CDC. Summary of Notifiable Diseases—United States, 2001. MMWR. 2003;50(53).
3.
Schuchat A, Robinson K, Wenger J, et al.Bacterial meningitis in the United States in 1995. N Engl J Med. 1997;337:970.
4.
CDC. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (AICP). MMWR. 2000;19(RR-7):1.
5.
Lingappa J, Rosenstein N, Zell E, et al.Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine. 2001;19:4566.
6.
CDC. Active bacterial core surveillance (ABCs) Report, Emerging Infections Program Network, Neisseria meningitidis 2000. ABCs/NETSS2002.
7.
Rosenstein N, Levine O, Taylor J, et al.Efficacy of meningococcal vaccine and barriers to vaccination. JAMA. 1998;279(6):435.
8.
Harrison LH, Dwyer DM, Maples CT, et al.Risk of meningococcal infection in college students. JAMA. 1999;281 (20):1906.
9.
Lepow M, Perkins B, Hughes P, et al.Meningococcal vaccines. In Plotkin S (ed): Vaccines, 3rd ed.Philadelphia: WB Saunders, 2003; Chapter 34.
10.
Ceesay S, Allen S, Menon A, et al.Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect on booster immunization. J Infect Dis. 1993;167:1212.
11.
Mitchell L, Ochnio J, Glover C, et al.Analysis of meningococcal serogroup C-Specific antibody levels in British Columbian Children and Adolescents. J Infect Dis. 1996;173:1009.
12.
Lieberman J, Shiu S, Wong V, et al.Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in small children—A randomized controlled trial. JAMA. 1996;275(19):1499.
13.
Campagne G, Barba A, Fabre P, et al.Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J. 2000;19:144.
14.
Leach A, Twamasi P, Kuman S, et al.Induction of immunologic memory in gambian children by vaccination in infancy with group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis. 1997;175:200.
15.
MacLennan J, Obaro S, Deeks J, et al.Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine. 1999;17(23-24):3086.
16.
Richmond P, Borrow R, Miller E, et al.Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis. 1999;179:1569.
17.
Borrow R, Goldblatt D, Andrews N, et al.Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis. 2002;186:1353.
18.
McVernon J, Maclennan J, Buttery J, et al.Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr Infect Dis J. 2002;21:747.
19.
MacLennan J, Obaro S, Deeks J, et al.Immunologic memory of 5 years after meningococcal A/C conjugate vaccination in infancy. J Infect Dis. 2001;183:97.
20.
Zhang Q, Pettitt E, Burkinshaw R, et al.Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants. Pediatr Infect Dis J. 2002;21:209.
21.
Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(Suppl 1):S58.
22.
Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002;359(9320):1829.
23.
Ramsay M, Andrews N, Trotter C, et al.Herd immunity from meningococcal serogroup C conjugate vaccination in England: Database analysis. BMJ. 2003;326:365.
24.
Trotter CL, Andrews NJ, Kaczmarski EB, et al.Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364(9431):365.
25.
Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol. 2002;51(9):717.
26.
Pichichero M, Casey J, Blatter M, et al.Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J. 2005;24(1):57.
27.
Granoff DM, Harris SL. Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J. 2004;23(6):490.
28.
Pichichero M, Casey J, Papa T, et al.A tetravalent (A, C, Y, and W-135) meningococcal diptheria toxoid conjugate vaccine, MCV-4, established immune memory in 2-3-year-old children after a single dose. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004; Washington, DC.
29.
Keyserling H, Papa T, Bybel M. A comparative trial of the safety and immunogenicity of an experimental tetravalent meningococcal (A, C, Y, A-135) diphtheria conjugate vaccine vs. a licensed meningococcal (A, C, Y, and W-135) polysaccharide vaccine in healthy adolescents. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003; Chicago, IL.
30.
Keyserling H, Rothstein E, Blatter M, et al.Augmentation of the immune response to a quadrivalent meningococcal (A, C, Y, W-135) diphtheria conjugate vaccine (MCV-4) by co-administration with tetanus-diphtheria vaccine (Td) in healthy adolescents. [Abstract 1044]. Presented at the 42nd Annual Meeting of Infectious Diseases Society of America, 2004; Boston, MA.
